SEC Form 4 · accession 0000899243-17-027953
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 par value per shareF1 | Dec 1, 2017 | S | 500,000 | $21.40 | D | 508,141 | I | Held by AstraZeneca AB |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All of these securities are owned by AstraZeneca AB, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to indirectly beneficially own the shares held by AstraZeneca AB, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any. The principal business address of AstraZeneca AB is SE-151, 85 Sodertalje, Sweden.